SK6542002A3 - The use of antibodies for the production of pharmaceutical composition useful as vaccines - Google Patents
The use of antibodies for the production of pharmaceutical composition useful as vaccines Download PDFInfo
- Publication number
- SK6542002A3 SK6542002A3 SK654-2002A SK6542002A SK6542002A3 SK 6542002 A3 SK6542002 A3 SK 6542002A3 SK 6542002 A SK6542002 A SK 6542002A SK 6542002 A3 SK6542002 A3 SK 6542002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- antibodies
- tumor
- individual
- antibody
- associated antigens
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 229960005486 vaccine Drugs 0.000 title claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 87
- 102000036639 antigens Human genes 0.000 claims abstract description 84
- 108091007433 antigens Proteins 0.000 claims abstract description 84
- 239000000427 antigen Substances 0.000 claims abstract description 82
- 210000001124 body fluid Anatomy 0.000 claims abstract description 40
- 239000010839 body fluid Substances 0.000 claims abstract description 40
- 238000002255 vaccination Methods 0.000 claims abstract description 34
- 239000003446 ligand Substances 0.000 claims abstract description 25
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 13
- 238000001261 affinity purification Methods 0.000 claims abstract description 11
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 11
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 32
- 210000002966 serum Anatomy 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 27
- 230000028993 immune response Effects 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000000777 hematopoietic system Anatomy 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 230000000955 neuroendocrine Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 229940021993 prophylactic vaccine Drugs 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000000872 buffer Substances 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 238000009833 condensation Methods 0.000 description 13
- 230000005494 condensation Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000003950 B-cell lymphoma Diseases 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 241000282560 Macaca mulatta Species 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 229940037642 autologous vaccine Drugs 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000013024 dilution buffer Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 3
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000002306 biochemical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012537 formulation buffer Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- -1 GM-CSF Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 2
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0192799A AT409086B (de) | 1999-11-16 | 1999-11-16 | Neue verwendung von antikörpern als impfstoffe |
| PCT/EP2000/011306 WO2001035989A2 (de) | 1999-11-16 | 2000-11-15 | Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK6542002A3 true SK6542002A3 (en) | 2002-11-06 |
Family
ID=3524036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK654-2002A SK6542002A3 (en) | 1999-11-16 | 2000-11-15 | The use of antibodies for the production of pharmaceutical composition useful as vaccines |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1229936B1 (zh) |
| JP (1) | JP2003514028A (zh) |
| KR (1) | KR20020060968A (zh) |
| CN (1) | CN1390138A (zh) |
| AT (1) | AT409086B (zh) |
| AU (1) | AU780853B2 (zh) |
| BR (1) | BR0015597A (zh) |
| CA (1) | CA2391927A1 (zh) |
| CZ (1) | CZ20021707A3 (zh) |
| DE (1) | DE50006526D1 (zh) |
| DK (1) | DK1229936T3 (zh) |
| EE (1) | EE200200252A (zh) |
| ES (1) | ES2218272T3 (zh) |
| HU (1) | HUP0204216A2 (zh) |
| IL (1) | IL149614A0 (zh) |
| IS (1) | IS6381A (zh) |
| MX (1) | MXPA02004942A (zh) |
| NO (1) | NO20022333L (zh) |
| NZ (1) | NZ518669A (zh) |
| PL (1) | PL356770A1 (zh) |
| PT (1) | PT1229936E (zh) |
| SK (1) | SK6542002A3 (zh) |
| TR (1) | TR200401267T4 (zh) |
| WO (1) | WO2001035989A2 (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017108A (en) * | 1975-04-17 | 1977-04-12 | Archibald Kenrick And Sons Limited | Window stay |
| US6294171B2 (en) * | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
| AT410172B (de) * | 2000-03-21 | 2003-02-25 | Igeneon Gmbh | Verfahren zur herstellung einer vakzineformulierung |
| AT410637B (de) * | 2001-06-01 | 2003-06-25 | Igeneon Krebs Immuntherapie | Verwendung von polyklonalen immunglobulinen |
| AT502293B1 (de) * | 2002-05-15 | 2008-03-15 | Igeneon Krebs Immuntherapie | Immunogener, monoklonaler antikörper |
| AT500648B1 (de) * | 2002-08-12 | 2010-03-15 | Igeneon Krebs Immuntherapie | Set zur behandlung von krebspatienten |
| KR100522526B1 (ko) * | 2002-11-28 | 2005-10-19 | 주식회사 바이넥스 | 면역 치료용 수지상 세포의 제조방법 |
| AT500650B1 (de) | 2003-04-17 | 2009-11-15 | Altropus Gmbh | Immunogener rekombinanter antikörper |
| WO2007024825A2 (en) * | 2005-08-26 | 2007-03-01 | Genway Biotech, Inc. | Immunoaffinity separation and analysis compositions and methods |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| US20180008702A1 (en) * | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984002848A1 (en) * | 1983-01-28 | 1984-08-02 | Centocor Inc | Anti-idiotypic antibodies to t cell antigen receptors |
| NZ229159A (en) * | 1988-05-17 | 1992-11-25 | Soldano Ferrone | Anti-idiotype antibodies which bind to the idiotype of murine antibody 225.28 |
| US20030072751A1 (en) * | 1990-03-14 | 2003-04-17 | Heribert Bohlen | Idiotypic vaccination against b cell lymphoma |
| IT1254315B (it) * | 1992-03-27 | 1995-09-14 | Mini Ricerca Scient Tecnolog | Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf. |
| CA2139756A1 (en) * | 1992-07-08 | 1994-01-20 | Eric M. Bonnem | Use of gm-csf as a vaccine adjuvant |
| AU704829B2 (en) * | 1994-12-28 | 1999-05-06 | University Of Kentucky | Murine anti-idiotype antibody 3H1 |
-
1999
- 1999-11-16 AT AT0192799A patent/AT409086B/de not_active IP Right Cessation
-
2000
- 2000-11-15 CA CA002391927A patent/CA2391927A1/en not_active Abandoned
- 2000-11-15 EE EEP200200252A patent/EE200200252A/xx unknown
- 2000-11-15 AU AU23572/01A patent/AU780853B2/en not_active Ceased
- 2000-11-15 DK DK00987250T patent/DK1229936T3/da active
- 2000-11-15 NZ NZ518669A patent/NZ518669A/en unknown
- 2000-11-15 MX MXPA02004942A patent/MXPA02004942A/es unknown
- 2000-11-15 KR KR1020027006126A patent/KR20020060968A/ko not_active Application Discontinuation
- 2000-11-15 EP EP00987250A patent/EP1229936B1/de not_active Expired - Lifetime
- 2000-11-15 PL PL00356770A patent/PL356770A1/xx not_active Application Discontinuation
- 2000-11-15 HU HU0204216A patent/HUP0204216A2/hu unknown
- 2000-11-15 DE DE50006526T patent/DE50006526D1/de not_active Expired - Fee Related
- 2000-11-15 ES ES00987250T patent/ES2218272T3/es not_active Expired - Lifetime
- 2000-11-15 PT PT00987250T patent/PT1229936E/pt unknown
- 2000-11-15 CN CN00815789A patent/CN1390138A/zh active Pending
- 2000-11-15 WO PCT/EP2000/011306 patent/WO2001035989A2/de not_active Application Discontinuation
- 2000-11-15 TR TR2004/01267T patent/TR200401267T4/xx unknown
- 2000-11-15 SK SK654-2002A patent/SK6542002A3/sk not_active Application Discontinuation
- 2000-11-15 BR BR0015597-7A patent/BR0015597A/pt not_active IP Right Cessation
- 2000-11-15 JP JP2001537979A patent/JP2003514028A/ja active Pending
- 2000-11-15 CZ CZ20021707A patent/CZ20021707A3/cs unknown
- 2000-11-15 IL IL14961400A patent/IL149614A0/xx unknown
-
2002
- 2002-05-14 IS IS6381A patent/IS6381A/is unknown
- 2002-05-15 NO NO20022333A patent/NO20022333L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1229936A2 (de) | 2002-08-14 |
| NO20022333L (no) | 2002-06-03 |
| CZ20021707A3 (cs) | 2002-10-16 |
| TR200401267T4 (tr) | 2004-07-21 |
| MXPA02004942A (es) | 2003-10-14 |
| EP1229936B1 (de) | 2004-05-19 |
| CN1390138A (zh) | 2003-01-08 |
| AU2357201A (en) | 2001-05-30 |
| DK1229936T3 (da) | 2004-08-30 |
| PL356770A1 (en) | 2004-07-12 |
| NO20022333D0 (no) | 2002-05-15 |
| ATA192799A (de) | 2001-10-15 |
| CA2391927A1 (en) | 2001-05-25 |
| ES2218272T3 (es) | 2004-11-16 |
| NZ518669A (en) | 2003-08-29 |
| IL149614A0 (en) | 2002-11-10 |
| EE200200252A (et) | 2003-06-16 |
| PT1229936E (pt) | 2004-09-30 |
| HUP0204216A2 (en) | 2003-04-28 |
| KR20020060968A (ko) | 2002-07-19 |
| IS6381A (is) | 2002-05-14 |
| BR0015597A (pt) | 2002-07-23 |
| AU780853B2 (en) | 2005-04-21 |
| WO2001035989A2 (de) | 2001-05-25 |
| WO2001035989A3 (de) | 2001-10-04 |
| DE50006526D1 (de) | 2004-06-24 |
| JP2003514028A (ja) | 2003-04-15 |
| AT409086B (de) | 2002-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8444974B2 (en) | Use of antibodies for the vaccination against cancer | |
| WO2001012217A9 (en) | Therapeutic antibody against muc-1 antigen and methods for their use | |
| KR20020011137A (ko) | 면역 반응을 개시시키기 위해 다중 에피토프 항원의입체형태를 변화시키기 위한 방법 및 조성물 | |
| SK6542002A3 (en) | The use of antibodies for the production of pharmaceutical composition useful as vaccines | |
| Roehnisch et al. | Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model | |
| US20060018901A1 (en) | Use of antibodies in a very low dose for the vaccination against cancer | |
| US20040191242A1 (en) | Method for producing a vaccine | |
| US20040265318A1 (en) | Use of antibodies for the vaccination against cancer | |
| KR100372958B1 (ko) | 면역반응을개시시키기위해다중에피토프항원의입체형태를변화시키기위한방법및조성물 | |
| JP2001055341A (ja) | 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物 | |
| JP2004002481A (ja) | 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物 | |
| MXPA98009586A (en) | Method and composition for the reconformation of multi-peptide antigens to start an animal response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |